NZ601818A - Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers - Google Patents

Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers

Info

Publication number
NZ601818A
NZ601818A NZ60181811A NZ60181811A NZ601818A NZ 601818 A NZ601818 A NZ 601818A NZ 60181811 A NZ60181811 A NZ 60181811A NZ 60181811 A NZ60181811 A NZ 60181811A NZ 601818 A NZ601818 A NZ 601818A
Authority
NZ
New Zealand
Prior art keywords
seq
treatment
cancer
cancers
tumor
Prior art date
Application number
NZ60181811A
Other languages
English (en)
Inventor
Steffen Walter
Toni Weinschenk
Harpreet Singh
Jens Fritsche
Peter Lewandrowski
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Publication of NZ601818A publication Critical patent/NZ601818A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
NZ60181811A 2010-03-19 2011-03-16 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers NZ601818A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31571510P 2010-03-19 2010-03-19
GB201004575A GB201004575D0 (en) 2010-03-19 2010-03-19 Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
PCT/EP2011/053996 WO2011113872A1 (en) 2010-03-19 2011-03-16 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers

Publications (1)

Publication Number Publication Date
NZ601818A true NZ601818A (en) 2014-09-26

Family

ID=42227968

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ60181811A NZ601818A (en) 2010-03-19 2011-03-16 Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers

Country Status (21)

Country Link
US (2) US10159725B2 (enExample)
EP (1) EP2547691B1 (enExample)
JP (1) JP5689140B2 (enExample)
KR (1) KR101620132B1 (enExample)
CN (1) CN102892777B (enExample)
AU (1) AU2011229177B2 (enExample)
BR (1) BR112012023621A2 (enExample)
CA (1) CA2793389A1 (enExample)
EA (1) EA022743B1 (enExample)
ES (1) ES2593409T3 (enExample)
GB (1) GB201004575D0 (enExample)
HU (1) HUE030000T2 (enExample)
MX (1) MX2012010814A (enExample)
MY (1) MY162850A (enExample)
NZ (1) NZ601818A (enExample)
PH (1) PH12012501822A1 (enExample)
PL (1) PL2547691T3 (enExample)
SG (1) SG183938A1 (enExample)
TW (1) TWI533882B (enExample)
UA (1) UA109891C2 (enExample)
WO (1) WO2011113872A1 (enExample)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
WO2012139094A2 (en) 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
US9452212B2 (en) 2011-04-14 2016-09-27 Dynavax Technologies Corporation Methods and compositions for eliciting an immune response against hepatitis B virus
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
ES2699817T3 (es) * 2012-03-19 2019-02-12 Stemline Therapeutics Inc Métodos para tratar y controlar el estado de un cáncer
WO2014010229A1 (en) * 2012-07-10 2014-01-16 Oncotherapy Science, Inc. Cdca1 epitope peptides for th1 cells and vaccines containing the same
KR20140100419A (ko) * 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 ｗｔ1 펩티드 암 백신 조성물
SG11201507328RA (en) * 2013-03-19 2015-10-29 Globeimmune Inc Yeast-based immunotherapy for chordoma
TWI775117B (zh) * 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9340800B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College Extended DNA-sensing GRNAS
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
WO2016011432A2 (en) * 2014-07-17 2016-01-21 Czerniecki Brian J Identification of immunogenic mhc class ii peptides for immune-based therapy
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2016115253A1 (en) * 2015-01-14 2016-07-21 The Regents Of The University Ofcolordo, A Body Corporate Insulin mimotopes and methods of using the same
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
MX2017017148A (es) * 2015-07-06 2018-02-23 Immatics Biotechnologies Gmbh Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra cancer esofagico y otros canceres.
EP3331552B1 (en) 2015-08-03 2021-01-27 Globeimmune, Inc. Modified yeast-brachyury immunotherapeutic compositions
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and uses thereof
GB201520597D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
TWI765875B (zh) 2015-12-16 2022-06-01 美商磨石生物公司 新抗原辨識、製造及用途
GB201603568D0 (en) * 2016-03-01 2016-04-13 Immatics Biotechnologies Gmbh Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
IL302705A (en) 2016-03-01 2023-07-01 Immatics Biotechnologies Gmbh Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
JP7035534B2 (ja) * 2016-03-28 2022-03-15 東レ株式会社 免疫誘導剤
CA3059210C (en) 2016-05-19 2022-07-19 The Regents Of The University Of California Triple drug combination (metformin, simvastatin, digoxin) for targeted treatment of pancreatic cancer
AU2017306676B2 (en) 2016-08-03 2024-02-22 President And Fellows Of Harvard College Adenosine nucleobase editors and uses thereof
US11542509B2 (en) 2016-08-24 2023-01-03 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
TWI796299B (zh) * 2016-08-26 2023-03-21 德商英麥提克生物技術股份有限公司 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
US11583575B2 (en) 2016-09-06 2023-02-21 Roche Sequencing Solutions, Inc. MHC-bound peptide arrays and methods of use thereof
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
JP7437939B2 (ja) * 2017-03-03 2024-02-26 トレオス バイオ リミテッド 集団に基づいた免疫原性ペプチドの同定のプラットフォーム
EP3592853A1 (en) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression of pain by gene editing
WO2018165631A1 (en) * 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
WO2018165629A1 (en) 2017-03-10 2018-09-13 President And Fellows Of Harvard College Cytosine to guanine base editor
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
US11911451B2 (en) * 2017-08-22 2024-02-27 ImmuLogix Ltd Composition of tumor-associated proliferative peptides and related anti-cancer immunogen for the treatment of lung cancers and other cancers
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
DK3773689T5 (da) * 2018-04-11 2024-08-19 Enterome S A Antigene peptider til forebyggelse og behandling af kræft
EP3797160A1 (en) 2018-05-23 2021-03-31 The Broad Institute Inc. Base editors and uses thereof
WO2020014261A1 (en) 2018-07-09 2020-01-16 The Broad Institute, Inc. Rna programmable epigenetic rna modifiers and uses thereof
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
GB201814362D0 (en) * 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020154500A1 (en) 2019-01-23 2020-07-30 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
BR112021018607A2 (pt) 2019-03-19 2021-11-23 Massachusetts Inst Technology Métodos e composições para editar sequências de nucleotídeos
EP3956349A1 (en) 2019-04-17 2022-02-23 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
EP3962524A4 (en) * 2019-05-02 2023-06-14 Surge Therapeutics, Inc. CANCER TREATMENT
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021155501A1 (zh) * 2020-02-05 2021-08-12 瓦克斯恩有限公司 生存素与gm-csf的融合体、编码dna、重组表达载体、抗肿瘤疫苗及其应用
AU2021267940A1 (en) 2020-05-08 2022-12-08 President And Fellows Of Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN116143950A (zh) * 2021-09-24 2023-05-23 武汉百英诺生物科技有限公司 一种抑制肿瘤侵袭转移的多肽组合及其应用
CN114959031A (zh) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 胰腺腺癌预后评估的标志物组合及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA725596A (en) 1960-08-26 1966-01-11 J. Wretlind Arvid Method of preparing intravenously injectable fat emulsions free from side reactions or complications
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2345440A1 (en) 1998-10-05 2000-04-13 Charles A. Nicolette Genes differentially expressed in cancer cells to design cancer vaccines
EP1538163A3 (en) 2000-11-01 2005-06-15 Insight Biotechnology Limited Phosphorylated Amyloid-Beta 1-43 Protein and its use in the treatment of Alzheimer's disease
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US20050221350A1 (en) * 2002-05-29 2005-10-06 Toni Weinschenk Method for identifying immunoreactive peptides
DE10225139A1 (de) * 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
ES2319286T3 (es) 2004-10-02 2009-05-06 Immatics Biotechnologies Gmbh Epitopos inmunogenos de linfocitos t colaboradores de antigenos de tumor humanos y utilizacion de dichos epitopos en metodos inmunoterapeuticos.
WO2007005635A2 (en) 2005-07-01 2007-01-11 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mitotic spindle protein aspm as a diagnostic marker for neoplasia and uses therefor
DK1760088T3 (da) 2005-09-05 2008-06-09 Immatics Biotechnologies Gmbh Tumor associerede peptider, der bindes promiskuöst til human leuko-cyt-antigen (HLA) klasse II-molekyler
EP1760089B1 (en) 2005-09-05 2009-08-19 Immatics Biotechnologies GmbH Tumor-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules and related anti-cancer vaccine
US20070218512A1 (en) 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
NZ582822A (en) * 2007-07-27 2012-06-29 Immatics Biotechnologies Gmbh Novel immunogenic epitopes for immunotherapy
EP2178557B1 (en) 2007-07-27 2017-03-01 Immatics Biotechnologies GmbH Composition of tumour-associated peptides and related anti-cancer vaccine
SI2113253T1 (sl) 2008-04-30 2010-06-30 Immatics Biotechnologies Gmbh Nove formulacije s tumorjem povezanih peptidov ki se vežejo na molekule humanega levkocitnega antigena HLA razreda I ali II za cepiva
SI2119726T2 (en) * 2008-05-14 2018-03-30 Immatics Biotechnologies Gmbh New and powerful Class II MHC peptides derived from survivin and neurocane
TWI526219B (zh) * 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
US20110318380A1 (en) * 2008-10-01 2011-12-29 Dako Denmark A/S MHC Multimers in Cancer Vaccines and Immune Monitoring
GB201004551D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9

Also Published As

Publication number Publication date
UA109891C2 (uk) 2015-10-26
US20110229524A1 (en) 2011-09-22
KR101620132B1 (ko) 2016-05-12
ES2593409T3 (es) 2016-12-09
EP2547691B1 (en) 2016-06-29
CA2793389A1 (en) 2011-09-22
CN102892777B (zh) 2017-02-08
US9132177B2 (en) 2015-09-15
WO2011113872A1 (en) 2011-09-22
PL2547691T3 (pl) 2016-12-30
SG183938A1 (en) 2012-10-30
BR112012023621A2 (pt) 2017-07-18
AU2011229177B2 (en) 2014-09-25
AU2011229177A1 (en) 2012-09-06
US10159725B2 (en) 2018-12-25
HK1180701A1 (zh) 2013-10-25
JP5689140B2 (ja) 2015-03-25
HUE030000T2 (en) 2017-04-28
JP2013522276A (ja) 2013-06-13
GB201004575D0 (en) 2010-05-05
MX2012010814A (es) 2012-11-12
TWI533882B (zh) 2016-05-21
PH12012501822A1 (en) 2019-07-10
EA022743B1 (ru) 2016-02-29
EP2547691A1 (en) 2013-01-23
TW201201834A (en) 2012-01-16
CN102892777A (zh) 2013-01-23
KR20130057428A (ko) 2013-05-31
MY162850A (en) 2017-07-31
US20130115188A1 (en) 2013-05-09
EA201201305A1 (ru) 2013-02-28

Similar Documents

Publication Publication Date Title
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
PH12016500949B1 (en) Novel immunotherapy against several tumors including gastrointestinal and gastric cancer
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012008998A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX2012009000A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
UA103202C2 (ru) Фармацевтическая композиция опухолеассоциированных пептидов и ее применение для лечения раковых заболеваний
PH12014501642A1 (en) Peptide vaccines for cancers expressing tumor-associated antigens
MX2012002502A (es) Conjugados de polietilenglicol/peptidos enlazados por disulfuro para la transfeccion de acidos nucleicos.
PE20240778A1 (es) Nuevos peptidos y combinacion de peptidos para usar en inmuterapia contra el cancer esofagico y otros canceres
NZ601677A (en) Improved cancer therapy based on tumor associated antigens derived from cyclin d1
IN2014DN09963A (enExample)
NZ708990A (en) Method for activating helper t cell
SG10201407944TA (en) Imp-3 oligopeptides and vaccines including the same
NZ609916A (en) Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201019331D0 (en) Methods for the diagnosis and treatment of cancer based on AVL9
PH12014500720A1 (en) Topk peptides and vaccines including the same
MX2012011668A (es) Peptidos cdca5 y vacunas que incluyen los mismos.
GB201018125D0 (en) Peptide
WO2011133216A3 (en) Mutant nis protein and uses thereof
WO2011006084A3 (en) Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof
CA2755897A1 (en) Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
RU2013149175A (ru) Лекарственное средство, содержащее лектины омелы, для лечения злокачественной меланомы
TH138998A (th) Cdca5 เปปไทด์ และ วัคซีนที่รวมถึงสิ่งเดียวกันนั้น

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2016 BY PIZZEYS PATENT AND TRADE MARK ATTORNEYS

Effective date: 20150505

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2017 BY PAVIS EG

Effective date: 20160311

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2018 BY PAVIS GMBH

Effective date: 20170303

LAPS Patent lapsed